These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 24242040

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Future neuroprotective strategies.
    Sättler MB, Bähr M.
    Exp Neurol; 2010 Sep; 225(1):40-7. PubMed ID: 19716365
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
    Aharoni R.
    Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
    [Abstract] [Full Text] [Related]

  • 7. [Neuroprotective approaches in neurology - dashed hopes?].
    Zipp F.
    Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S12-3. PubMed ID: 24242029
    [No Abstract] [Full Text] [Related]

  • 8. Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis.
    Nathoo N, Yong VW, Dunn JF.
    Mult Scler; 2014 Jan; 20(1):3-11. PubMed ID: 24263386
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
    Forte M, Gold BG, Marracci G, Chaudhary P, Basso E, Johnsen D, Yu X, Fowlkes J, Rahder M, Stem K, Bernardi P, Bourdette D.
    Proc Natl Acad Sci U S A; 2007 May 01; 104(18):7558-63. PubMed ID: 17463082
    [Abstract] [Full Text] [Related]

  • 11. [Recent advances in pathogenesis and therapy of multiple sclerosis].
    Linker RA, Stadelmann C, Diem R, Bähr M, Brück W, Gold R.
    Fortschr Neurol Psychiatr; 2005 Dec 01; 73(12):715-27. PubMed ID: 16355314
    [Abstract] [Full Text] [Related]

  • 12. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
    Morsali D, Bechtold D, Lee W, Chauhdry S, Palchaudhuri U, Hassoon P, Snell DM, Malpass K, Piers T, Pocock J, Roach A, Smith KJ.
    Brain; 2013 Apr 01; 136(Pt 4):1067-82. PubMed ID: 23518709
    [Abstract] [Full Text] [Related]

  • 13. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis.
    Diem R, Sättler MB, Merkler D, Demmer I, Maier K, Stadelmann C, Ehrenreich H, Bähr M.
    Brain; 2005 Feb 01; 128(Pt 2):375-85. PubMed ID: 15601662
    [Abstract] [Full Text] [Related]

  • 14. C16 peptide shown to prevent leukocyte infiltration and alleviate detrimental inflammation in acute allergic encephalomyelitis model.
    Fang M, Sun Y, Hu Z, Yang J, Davies H, Wang B, Ling S, Han S.
    Neuropharmacology; 2013 Jul 01; 70():83-99. PubMed ID: 23352465
    [Abstract] [Full Text] [Related]

  • 15. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T.
    Pharmacol Ther; 2010 Apr 01; 126(1):82-93. PubMed ID: 20122960
    [Abstract] [Full Text] [Related]

  • 16. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis.
    Kipp M, Beyer C.
    Front Neuroendocrinol; 2009 Jul 01; 30(2):188-200. PubMed ID: 19393685
    [Abstract] [Full Text] [Related]

  • 17. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R.
    J Neurol Sci; 2009 Dec 01; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [Abstract] [Full Text] [Related]

  • 18. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
    Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R.
    J Neuroimmunol; 2012 Oct 15; 251(1-2):14-24. PubMed ID: 22749337
    [Abstract] [Full Text] [Related]

  • 19. Experimental models of multiple sclerosis.
    Pachner AR.
    Curr Opin Neurol; 2011 Jun 15; 24(3):291-9. PubMed ID: 21519255
    [Abstract] [Full Text] [Related]

  • 20. Neuroprotective agents: cannabinoids.
    Sánchez AJ, García-Merino A.
    Clin Immunol; 2012 Jan 15; 142(1):57-67. PubMed ID: 21420365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.